Data on demographic characteristics, medical history, and medications were collected at baseline. Body weight, blood pressure, and heart rate were recorded, and hematology, blood chemistry, C-reactive protein (CRP), antistreptolysin-O (ASO), and blood sugar tests were performed. Each patient underwent an X-ray with an anteroposterior (AP) view of chest/hands/wrist/foot and 12-lead electrocardiography as well as a 28-joint assessment for tender joint count, swollen joint count, and duration of morning stiffness.
The primary endpoint was reduction in DAS28, a composite index based on the assessment of 28 joints, the erythrocyte (red blood cell) sedimentation rate (ESR), and visual analog scales (VAS) on which the patient scored his/her global assessment of disease activity. The secondary endpoints included ACR criteria scores. The ACR measures the improvement in tenderness or swollen joint counts and improvement in three of 5 parameters: patient global assessment, physician assessment, pain scale disability, functional questionnaire – HAQ (Health Assessment Questionnaire), and acute phase reactant (such as ESR).
There was no significant difference in any baseline characteristics between the groups. Thirty-eight patients completed the study and were included for efficacy analyses; all 45 patients were included in safety assessments. No explanation is given as to the reasons 7 patients did not complete the study.
There was a statistically significant change in DAS28 scores compared to baseline of similar proportion for all 3 treatment groups after 8 weeks (all P<0.05). There was no significant difference among the groups. Likewise, each group had a statistically significant difference in the ESR and VAS (all P<0.05) compared to baseline, but not among groups; curcumin extract had the highest percentage change of the 3 groups for VAS (59.9%). There was also a statistically significant change in ACR scores in all 3 treatment groups (all P<0.05), but no difference among them. The authors report that the percentage change in ACR was greatest for curcumin. CRP showed a significant change only in the curcumin group (P<0.05).
Adverse events were reported more frequently in the diclofenac sodium group and included itching and swelling around the eyes, dimness of vision, and worsening of the condition. Adverse events reported in the curcumin group were mild fever and throat infection (which are not necessarily associated with the use of the curcumin).
This pilot study shows that BCM-95 curcumin reduced DAS28 and ACR scores in patients with RA alone or in combination with diclofenac sodium. It also showed that intake levels of 500 mg twice daily for 8 weeks yielded few adverse effects. The mechanism for this action is not known but is purported to be due to the effect of curcumin on multiple signaling pathways involved with pain and inflammation. The authors reported that BCM-95 curcumin was selected for use in this study based on its enhanced absorption, which has been shown in 2 previously published human studies to have up to 7 times increased absorption than generic 95% curcumin turmeric extracts based on area under the curve (AUC) and 10 times the serum peak of generic 95% curcumin extracts.1,2
The authors conclude by asserting that BCM-95 curcumin extract was the superior treatment in this study, based on its efficacy equaling the prescription drug diclofenac sodium on DAS28 and ACR scores, combined with its superior safety and lower adverse effect profile. What can be said is that this proprietary curcumin extract had a similar effectiveness to the prescription drug diclofenac sodium with few adverse side effects. Larger studies will help to shed light on these findings.
Reviewed: Chandran B, Goel A. A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother Res. March 9, 2012. [Epub ahead of print]. doi: 10.1002/ptr.4639.
—Risa Schulman, PhD
by Risa N. Schulman
First appeared HerbalGram. 2012; American Botanical Council